Table 4. Association between PD-L1 status and clinicopathologic variables in lung adenocarcinoma.

		PD-L1 IHC (number (%))				PD-L1 RNA scope (number (%))
	Total	Negative	Weak positive	Strong positive	p value	Negative	Positive	p value
Smoking history
Yes	192	156 (81.3%)	22 (11.5%)	14 (7.3%)	> 0.05	180 (93.8%)	12 (6.2%)	> 0.05
No	284	243 (85.6%)	26 (9.2%)	15 (5.3%)		267 (94.0%)	17 (6.0%)
Histologic subtype ¶
WD	42	41 (97.6%)	1 (2.4%)	0	<0.001	41 (97.6%)	1 (2.4%)	0.002
MD	360	309 (85.8%)	33 (9.2%)	18 (5.0%)		343 (95.3%)	17 (4.7%)
PD	68	43 (62.7%)	14 (20.9%)	11(16.4%)		57 (83.6%)	11 (16.4%)
Mucinous	6	6 (100%)	0	0		6 (100%)	0
Pathologic stage
IA-IIA	340	286 (84.1%)	33 (9.7%)	21 (6.2%)	> 0.05	320 (94.1%)	20 (5.9%)	> 0.05
IIB-IV	136	113 (83.1%)	15 (11.0%)	8 (5.9%)		127 (93.4%)	9 (6.6%)
EGFR mutation
Present	223	201 (90.1%)	17 (7.6%)	5 (2.2%)	0.001	216 (96.9%)	7 (3.1%)	0.016
Absent	229	179 (78.2%)	27 (11.8%)	23 (10.0%)		209 (91.3%)	20 (8.7%)
KRAS mutation
Present	23	15 (65.2%)	4 (17.4%)	4 (17.4%)	0.017	20 (87.0%)	3 (13.0%)	> 0.05
Absent	237	203 (85.7%)	23 (9.7%)	11 (4.6%)		223 (94.1%)	14 (5.9%)
ALK rearrangement
Present	24	21 (87.5%)	1 (4.2%)	2 (8.3%)	> 0.05	24 (100%)	0	> 0.05
Absent	181	161 (89.0%)	12 (6.6%)	8 (4.4%)		177 (97.8%)	4 (2.2%)

PD-L1, Programmed cell death ligand-1; IHC, immunohistochemistry; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; EGFR, Epidermal growth factor receptor; KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; ALK, Anaplastic lymphoma kinase.

^¶ lepidic, well differentiated; acinar and papillary, moderately differentiated; and micropapillary and solid, poorly differentiated.